The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00
Abstract
Purpose: Short imatinib pulses were added to chemotherapy to improve the long-term survival of adult patients with Philadelphia chromosome (Ph) –positive acute lymphoblastic leukemia (ALL), to optimize complete remission (CR) and stem-cell transplantation (SCT) rates. Patients and Methods: Of 94 total patients (age range, 19 to 66 years), 35 represented the control cohort (ie, imatinib-negative [IM-negative] group), and 59 received imatinib 600 mg/d orally for 7 consecutive days (ie, imatinib-positive [IM-positive] group), starting from day 15 of chemotherapy course 1 and from 3 days before chemotherapy during courses 2 to 8. Patients in CR were eligible for allogeneic SCT or, alternatively, for high-dose therapy with autologous SCT followed by long-term maintenance with intermittent imatinib. Results: CR and SCT rates were greater in the IM-positive group (CR: 92% v 80.5%; P = .08; allogeneic SCT: 63% v 39%; P = .041). At a median observation time of 5 years (range, 0.6 to 9.2 years), 22 patients in the IM-positive group versus five patients in the IM-negative group were alive in first CR (P = .037). Patients in the IM-positive group had significantly greater overall and disease-free survival probabilities (overall: 0.38 v 0.23; P = .009; disease free: 0.39 v 0.25; P = .044) and a lower incidence of relapse (P = .005). SCT-related mortality was 28% (ie, 15 of 54 patients), and postgraft survival probability was 0.46 overall. Conclusion: This imatinib-based protocol improved long-term outcome of adult patients with Ph-positive ALL. With SCT, post-transplantation mortality and relapse remain the major hindrance to additional therapeutic improvement. Additional intensification of imatinib therapy should warrant a better molecular response and clinical outcome, both in patients selected for SCT and in those unable to undergo this procedure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Gabert, J., Beillard, E., van der Velden, V. H. J., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J. M., Cavé, H., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403135 · Cited by 1,284
Thomas, D. A. (2004) · Blood · doi:10.1182/blood-2003-08-2958 · Cited by 571
Yanada, M., Takeuchi, J., Sugiura, I., Akiyama, H., Usui, N., Yagasaki, F., Kobayashi, T., Ueda, Y., Takeuchi, M., Miyawaki, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2177 · Cited by 454
Bassan, R., Spinelli, O., Oldani, E., Intermesoli, T., Tosi, M., Peruta, B., Rossi, G., Borlenghi, E., Pogliani, E. M., Terruzzi, E., et al. (2009) · Blood · doi:10.1182/blood-2008-11-185132 · Cited by 430
Self-citationVignetti, M., Fazi, P., Cimino, G., Martinelli, G., Di Raimondo, F., Ferrara, F., Meloni, G., Ambrosetti, A., Quarta, G., Pagano, L., et al. (2007) · Blood · doi:10.1182/blood-2006-10-052746 · Cited by 374
Bedi, A., Barber, J., Bedi, G., el-Deiry, W., Sidransky, D., Vala, M., Akhtar, A., Hilton, J., & Jones, R. (1995) · Blood · doi:10.1182/blood.v86.3.1148.1148 · Cited by 349
de Labarthe, A., Rousselot, P., Huguet-Rigal, F., Delabesse, E., Witz, F., Maury, S., Réa, D., Cayuela, J.-M., Vekemans, M.-C., Reman, O., et al. (2007) · Blood · doi:10.1182/blood-2006-03-011908 · Cited by 344
Cited by
Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
Foà, R., Bassan, R., Vitale, A., Elia, L., Piciocchi, A., Puzzolo, M.-C., Canichella, M., Viero, P., Ferrara, F., Lunghi, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2016272 · Cited by 522
Self-citationModern Therapy of Acute Lymphoblastic Leukemia
Bassan, R., & Hoelzer, D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1382 · Cited by 485
Self-citationHoelzer, D., Bassan, R., Dombret, H., Fielding, A., Ribera, J. M., & Buske, C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw025 · Cited by 463
Self-citationFoà, R., Vitale, A., Vignetti, M., Meloni, G., Guarini, A., De Propris, M. S., Elia, L., Paoloni, F., Fazi, P., Cimino, G., et al. (2011) · Blood · doi:10.1182/blood-2011-05-351403 · Cited by 462
Kantarjian, H., Thomas, D., Jorgensen, J., Jabbour, E., Kebriaei, P., Rytting, M., York, S., Ravandi, F., Kwari, M., Faderl, S., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70386-2 · Cited by 412
Metadata
- Authors
- Bassan, R., Rossi, G., Pogliani, E. M., Di Bona, E., Angelucci, E., Cavattoni, I., Lambertenghi-Deliliers, G., Mannelli, F., Levis, A., Ciceri, F., Mattei, D., Borlenghi, E., Terruzzi, E., Borghero, C., Romani, C., Spinelli, O., Tosi, M., Oldani, E., Intermesoli, T., & Rambaldi, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-08-01
- Volume
- 28
- Issue
- 22
- Pages
- 3644-3652
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2102929198
- Cited by
- 272
- References
- 28
- FWCI
- 19.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00. https://app.cochat.ai/papers/10.1200/jco.2010.28.1287
- The paper
- Bassan, R., Rossi, G., Pogliani, E. M., Di Bona, E., Angelucci, E., Cavattoni, I., Lambertenghi-Deliliers, G., Mannelli, F., Levis, A., Ciceri, F., Mattei, D., Borlenghi, E., Terruzzi, E., Borghero, C., Romani, C., Spinelli, O., Tosi, M., Oldani, E., Intermesoli, T., & Rambaldi, A. (2010). Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.28.1287
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.